U.S. Markets open in 3 hrs 21 mins

Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.

In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelics Industry News Stories for the Week of May 3rd – 9th, 2021.

Without further ado, let’s get started.

* Yahoo Finance readers, please click here to view the full article.

10. A Psychedelic Drug Passes a Big Test for PTSD Treatment

A New Study Shows That MDMA, Known as Ecstasy or Molly, Can Bring Relief When Paired With Talk Therapy to Those With Severe Post-Traumatic Stress Disorder

In an important step toward medical approval, MDMA, the illegal drug popularly known as Ecstasy or Molly, was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired with talk therapy.

READ FULL MDMA ARTICLE

9. Aurora Cannabis Supporting Medical Cannabis Educational Initiative in Germany

Students at Humboldt University of Berlin Can Now Expand Their Study of Medical Cannabis By Taking Part in an Interdisciplinary Cannabis Research Class

Canadian cannabis giant Aurora Cannabis (TSX: ACB) (NYSE: ACB) (FRA: 21P) via its Berlin-based subsidiary Aurora Europe is supporting a medical cannabis-related educational initiative in Germany with €38,000 ($46,198). Created by Humboldt University in 2013, the cannabis science course was conceived with the idea of designing the “scientific personalities of students.” According to the class’s website, the main idea of the program is to bring ancient cultivars back into use through science for the benefit of society.

READ FULL AURORA CANNABIS ARTICLE

8. Field Trip Health Announces Opening of Psychedelic-Enhanced Therapy Center in Houston; Locations of Next 5 Field Trip Health Centers

The Opening in Houston’s River Oaks District is Field Trip’s First Location in Texas With Construction Commencing in Other U.S. and Canadian Cities

Field Trip Health (CSE: FTRP) (OTC: FTRPF) announced today the opening of its fifth location in the United States in the city of Houston, TX. Located in the River Oaks District, the Houston location is the second Field Trip Health center to open this year. Field Trip also announced that it has entered into leases and has commenced, or will soon commence, construction to build Field Trip Health centers in San Diego, CA, San Carlos, CA, Seattle, WA, Washington DC and Fredericton, NB.

READ FULL FIELD TRIP ARTICLE

7. Alabama Lawmakers Pass Landmark Medical Cannabis Legalization Bill

The State Senate Already Had Approved the Alabama Compassionate Act, Senate Bill 46, by a 21-8 Vote in February After a Short Debate

Alabama took a major step toward becoming the 39th state in the nation to legalize a medical cannabis market, albeit a relatively restrictive one, after the House passed an amended bill by a vote of 68-34 Thursday.

READ FULL ALABAMA ARTICLE

6. Texas House Approves Psychedelics Research Bill as Marijuana Reform Measures Also Advance

The Texas House of Representatives on Thursday Approved a Bill That Would Require the State to Conduct a Study Into the Therapeutic Potential of Psychedelics like Psilocybin and MDMA

This comes as numerous marijuana reform measures move through the legislature. The legislation, sponsored by Rep. Alex Dominguez (D), passed by a vote of 134-12. It had advanced on second reading via a voice vote a day earlier. It now heads to the Senate.

READ FULL TEXAS ARTICLE

5. Oklahoma’s Cannabis Market: What Investors, Entrepreneurs Need to Know

Oklahoma’s Medical Cannabis Market is One of the More Unique

With lax regulations and a simple pathway to licensing, the state created a market with over 10,000 actively licensed dispensaries, growers, and processors for a state with approximately 644,000 registered patients as of 2019-2020.

READ FULL OKLAHOMA ARTICLE

4. Special Report: Psychedelics in Medicine Part 1: Psychedelics as a Potential Therapeutic Option for Psychiatric Conditions

Psychedelic Drugs, Such as Lysergic Acid Diethylamide (LSD), Was of Interest to Molecular Psychiatry in the 1950s Due to its Considerable Chemical Similarity to Serotonin (5-HT)

In the context of a highly regulated system, the use of psychedelics in psychiatry is not necessarily novel, but a reemerging concept. They are generally considered Schedule I controlled substances (psilocybin, DMT, MDMA), which traditionally are considered to purport no medical value and high potential for abuse.

READ FULL PSYCHEDELICS REPORT ARTICLE

3. Cannabis M&A Surges in Hot Pennsylvania Market With $400 Million in Deals

Cultivation and Processing Operations Are Fetching Over $100 Million and Dispensary Licenses Are Commanding Prices of $20 Million-$35 Million for Each Storefront as the State’s Retail Sector Consolidates

Merger and acquisition activity is sizzling in Pennsylvania, with more than $400 million worth of deals announced since March alone, as local cannabis businesses cash out and multistate operators seek or expand footholds in the rapidly growing mid-Atlantic market.

READ FULL CANNABIS M&A ARTICLE

2. A Psychedelic Drug Boom in Mental Health Treatment Comes Closer to Reality

New results From a Clinical Trial Using MDMA to Treat PTSD Showed the Promise of a Stigmatized Drug to Treat Mental Illness at a Time When Covid-19 Has Raised Global Awareness of the Toll of Mental Health Conditions

Decriminalization of drugs like “magic” mushrooms in places including Denver and Oregon may lead to broader public acceptance, but the emerging alternative drug industry is focused on patients most in need and where current psychiatric medications have failed. Companies like Compass Pathways (NASDAQ: CMPS), which uses psilocybin for depression, and ATAI Life Sciences, backed by Peter Thiel, are researching a variety of ways to treat mental health with alternative and psychedelic therapies.

READ FULL PSYCHEDELICS BOOM ARTICLE

1. Marijuana MSO Trulieve Buying Harvest Health in $2.1 Billion Mega-Deal

The Combined MSO Will Operate in 11 States, With a Total of 22 Growing and Processing Facilities and 126 Medical and Adult-Use Cannabis Dispensaries Stretching Across the United States

Florida-based Trulieve (CSE: TRUL) (OTCQX: TCNNF) announced an agreement to acquire Arizona-headquartered Harvest Health (CSE: HARV) (OTCQX: HRVSF) in an all-stock deal valued at about $2.1 billion and touted as the largest U.S. marijuana transaction to date.

READ FULL TRULIEVE ARTICLE

Image Sourced from Pixabay

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.